IL-33 promotes gastric tumour growth in concert with activation and recruitment of inflammatory myeloid cells

Chau P Tran,Michelle Scurr,Louise O'Connor,Jon N Buzzelli,Garrett Z Ng,Sharleen Chung Nien Chin,Lincon A Stamp,Toshinari Minamoto,Andrew S Giraud,Louise M Judd,Philip Sutton,Trevelyan R Menheniott,Chau P. Tran,Louise O’Connor,Jon N. Buzzelli,Garrett Z. Ng,Lincon A. Stamp,Andrew S. Giraud,Louise M. Judd,Trevelyan R. Menheniott
DOI: https://doi.org/10.18632/oncotarget.28238
2022-06-01
Oncotarget
Abstract:Interleukin-33 (IL-33) is an IL-1 family cytokine known to promote T-helper (Th) type 2 immune responses that are often deregulated in gastric cancer (GC). IL-33 is overexpressed in human gastric tumours suggesting a role in driving GC progression although a causal link has not been proven. Here, we investigated the impact of IL-33 genetic deficiency in the well-characterized <i>gp130</i> <sup>F/F</sup> mouse model of GC. Expression of IL-33 (and it's cognate receptor, ST2) was increased in human and mouse GC progression. IL-33 deficient <i>gp130</i> <sup>F/F</sup> <i>/Il33</i> <sup>-/-</sup> mice had reduced gastric tumour growth and reduced recruitment of pro-tumorigenic myeloid cells including key mast cell subsets and type-2 (M2) macrophages. Cell sorting of gastric tumours revealed that IL-33 chiefly localized to gastric (tumour) epithelial cells and was absent from tumour-infiltrating immune cells (except modest IL-33 enrichment within CD11b<sup>+</sup> CX3CR1<sup>+</sup>CD64<sup>+</sup>MHCII<sup>+</sup> macrophages). By contrast, ST2 was absent from gastric epithelial cells and localized exclusively within the (non-macrophage) immune cell fraction together with mast cell markers, Mcpt1 and Mcpt2. Collectively, we show that IL-33 is required for gastric tumour growth and provide evidence of a likely mechanism by which gastric epithelial-derived IL-33 drives mobilization of tumour-promoting inflammatory myeloid cells.
What problem does this paper attempt to address?